期刊文献+

慢性丙型病毒性肝炎的诊断与治疗 被引量:7

下载PDF
导出
摘要 自从发现丙型肝炎病毒(HCV)为非甲非乙型肝炎的病因之一以来,已过15个春秋,丙型病毒性肝炎对人民生命健康的危害仍在继续,然而其本质也在逐渐被人们所认识当今HCV的基础和临床各方面研究已经有了很大进展.但是在诊断、治疗、疫苗研制等方面还不尽如人意,彻底控制丙型肝炎的危害还有很远的路程要走.可以说,在丙型肝炎临床与科研过程中充满了艰辛,任重而道远.因此临床医生对丙型肝炎密切相关的诊疗预防等进展需求显得十分迫切.为了提高临床医生认识,改善国内对丙型肝炎的诊断治疗相对落后的现状,了解目前国内外最主要的研究动态.借今年美国肝病研究协会制定《丙型肝炎的诊断、治疗处理策略-临床实践指南(AASILD Practice Guideline)》及中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会制定《丙型肝炎防治指南》的机会,我们组织一批国内研究丙型肝炎的资深专家和教授撰写了“焦点论坛-慢性丙型肝炎的诊断与治疗”,这次“焦点论坛”主要面向临床医生,故在组稿写作过程中注意“紧扣文题,开门见山,突出重点,临床实用性为主,兼顾相关研究进展”,以进一步推动丙型肝炎的临床实用性研究.希望能在控制丙型肝炎的工作中履行义务,贡献一份薄力.
出处 《世界华人消化杂志》 CAS 2004年第10期2382-2385,共4页 World Chinese Journal of Digestology
  • 相关文献

参考文献15

  • 1Hino K, Okita K. Interferon therapy as chemopr vention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother 2004;53:19-22.
  • 2Ertriquez J, Gallego A, Torras X, Perez-Olmeda 1, Diago M,Soriano V, Lujan MS, Garcia-Samaniego J. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000;7:403-408.
  • 3Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ.Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163-168.
  • 4Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128-134.
  • 5Shiffman ML. Chronic hepatitis C. Semin Liver Dis 2004;24:S 1-2.
  • 6Cavalletto L, Chemello L, Donada C, Casarin P, Belussi F,Bernardinello E, Marino F, Pontisso P, Gatta A, Alberti A. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. Tvvh study group. J Hepatol 2000,33:128-134.
  • 7Berg T, Pascu M, Moiler B. Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements.Hepatology 2003;37:1495-1496.
  • 8Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Hosaka T, Kobayashi M,Kumada H. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy. J Gastroenterol 2004;39:455-460.
  • 9Fattovich G, Zagni I, Fornaciari G, Minola E, Fabris P, Boccia S, Giusti M, Abbati G, Felder M, Rovere P, Redaelli A, Tonon A, Montanari R, Paternoster C, Distasi M, Castagnetti E, Tositti G, Rizzo C, Suppressa S, Pantalena M, Lomonaco L, Scattolini C, Tagger A. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. J Viral Hepat 2003;10:111-117.
  • 10Dettmer RM, Reinus JF, Clain DJ, Aytaman A, Levendoglu H,Bloom AA, Isaacson MP,Spinnell M, Meyer D, Sarabanchong V, Zhang Y, Garcia-Carrasquillo RJ, Markowitz DD, Magun AM, Worman HJ. Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C. Hepatogastroenterology 2002;49:758-763.

同被引文献104

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部